Exploring Lipoprotein-Associated Phospholipase A2 Levels in Iraqi Patients with Stable Angina: Insights from Coronary Angiography Diagnosis

Aseel Ghassan Daoud; Wassan Abdul Kareem Abbas; Ahmed Yousif Hasan; Maha N. Abu Hajleh

doi:10.32947/ajps.v25i1.1121

Authors

Aseel Ghassan Daoud Department of Clinical Laboratory Sciences, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
Wassan Abdul Kareem Abbas Department of Clinical Laboratory Sciences, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
Ahmed Yousif Hasan Iraqi Center for Heart Diseases, Medical City Teaching Hospital, Baghdad, Iraq
Maha N. Abu Hajleh Department of Cosmetic Science, Pharmacological and Diagnostic Research Centre, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman, Jordan

DOI:

https://doi.org/10.32947/ajps.v25i1.1121

Keywords:

Coronary artery disease, diagnosis, left ventricular ejection fraction, lipoprotein-associated phospholipase A2, stable angina

Abstract

Stable angina is a prevalent heart disease which can be defined as a clinical syndrome of stable coronary artery disease (CAD) that refers to the presence of myocardial ischemia. Lipoprotein-associated Phospholipase A2 (Lp-PLA2) is an important biomarker of atherosclerosis progression through pro-inflammatory and anti-inflammatory effects.

Objective: The aim was to detect the role of Lp-PLA2 in the diagnosis of patients with stable angina and normal left ventricular ejection fraction (LVEF).

Patients and methods: The study design was a case-control study. 90 males and females (age 40-76 years) who were presented with chest pain were enrolled in the study, all were subjected to echocardiography, ECG and coronary angiography by the cardiologist. Besides, patient’s questionnaire and biochemical analysis were also used. According to the angiography, they were divided into two groups: 60 patients and 30 as a control group. Levels of Lp-PLA2, total cholesterol, triglycerides (TG), high density lipoprotein-Cholesterol (HDL-C), very low density lipoprotein-Cholesterol (VLDL-C) and low density lipoprotein-Cholesterol (LDL-C) in serum were assessed. The biplane M mode method was used to measure left ventricular ejection fraction (LVEF).

Result: It was detected that Lp-PLA2 serum levels were significantly higher in the patients than in the control, (P≤0.01). ROC analysis showed that Lp-PLA2 had specificity of 100% and sensitivity 100%.

Conclusion: Measurement of Lp-PLA2 can be applied as an excellent biomarker in the diagnosis of patients with stable angina and normal LV ejection fraction.

References

1- Ferraro R, Latina JM, Alfaddagh A, Michos ED, Blaha MJ, Jones SR, et al. Evaluation and Management of Patients with Stable Angina: Beyond the Ischemia Paradigm: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020 Nov 10;76(19):2252–66.

2- Tu M, Jiang Y, Yu J, Hu H, Liao B, He X, et al. Acupuncture for treating chronic stable angina pectoris associated anxiety and depression: A systematic review and meta-analysis. Complementary Therapies in Clinical Practice. 2021 Nov 1;45:101484.

3- Gillen C, Goyal A. Stable Angina. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 May 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559016/

4- Tamargo J, Lopez-Sendon J. Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina. Future Cardiology. 2022 Mar;18(3):235–51.

5- Doenst T, Haverich A, Serruys P, Bonow RO, Kappetein P, Falk V, et al. PCI and CABG for Treating Stable Coronary Artery Disease. Journal of the American College of Cardiology. 2019 Mar;73(8):964–76.

6- Criteria I of M (US) C on SSCD. Ischemic Heart Disease. In: Cardiovascular Disability: Updating the Social Security Listings [Internet]. National Academies Press (US); 2010 [cited 2023 May 5]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK209964/

7- Hussain HAK, Muftin NQ, Al-jibouri MN, Ben Salah G. Study of the Arginase Activity and Other Biochemical Parameters in Patients with Coronary Artery Disease in Baghdad Governorate-Iraq. Al-Mustansiriyah Journal of Science. 2023 Mar 30;34(1):37–44.

8- Bauersachs R, Zeymer U, Brière JB, Marre C, Bowrin K, Huelsebeck M. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. Cardiovasc Ther. 2019 Nov 26; 2019:8295054.

9- Gibbons RJ, Miller TD. Declining Accuracy of the Traditional Diamond-Forrester Estimates of Pretest Probability of Coronary Artery Disease: Time for New Methods. JAMA Intern Med. 2021 May 1;181(5):579–80.

10- Bertolone DT, Gallinoro E, Esposito G, Paolisso P, Bermpeis K, De Colle C, et al. Contemporary Management of Stable Coronary Artery Disease. High Blood Press Cardiovasc Prev. 2022;29(3):207–19.

11- Huang F, Wang K, Shen J. Lipoprotein‐associated phospholipase A2: The story continues. Medicinal Research Reviews. 2020 Jan;40(1):79.

12- Wang Y, Liu G, Song H, Cao C, Ji X, Cao G. Elevated Lipoprotein-Associated Phospholipase A2 Is Associated with Intracranial Atherosclerosis. Front Neurol. 2022 Jun 10; 13:858302.

13- Heriansyah T, Chomsy IN, Kumboyono K, Pratiwi PA, Wihastuti TA. Expression of Hypoxia-Inducible Factor-1α (HIF1A) and Lp-PLA2 in Low, Intermediate, and High Cardiovascular Disease Risk Population. Vasc Health Risk Manag. 2020 Dec 1;16:507–13.

14- Hassan M. STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A 2 (Lp-PLA 2 ) as a biomarker or risk factor for cardiovascular diseases. Global Cardiology Science and Practice. 2015 Jan;2015(1):6.

15- Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2021 Nov 30;78(22):e187–285.

16- Glover T. An Introduction to Biostatistics, Second Edition 2nd edition by Thomas Glover, Kevin Mitchell (2008) Paperback.

17- Forthofer RN, Lee ES, Hernandez M. Biostatistics: a guide to design, analysis, and discovery. 2nd ed. Burlington, MA: Elsevier Academic Press; 2007. 502 p.

18- Rieckmann N, Neumann K, Feger S, Ibes P, Napp A, Preuß D, et al. Health-related qualify of life, angina type and coronary artery disease in patients with stable chest pain. Health Qual Life Outcomes. 2020 May 14; 18:140.

19- Severino P, D’Amato A, Pucci M, Infusino F, Adamo F, Birtolo LI, et al. Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. Int J Mol Sci. 2020 Oct 30;21(21):8118.

20- Ali Sheikh MS. Diagnostic Role of Plasma MicroRNA-21 in Stable and Unstable Angina Patients and Association with Aging. Cardiol Res Pract. 2020 Apr 13;2020:9093151.

21- Shi S, Wang Z, Li S, Wu X, Wang P, Wang F. Yanyu Decoction for Aged Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2021 Apr 17;2021:6615035.

22- Soliman SE, Abouelenin MAH, Samy NI, Omar MM, Alrefai AA. Various Expressions of PIK3C2A and TXNIP Genes and Their Potential Role as Independent Risk Factors for Chronic Stable Angina and Acute Coronary Syndrome. Biomolecules. 2023 Feb 6;13(2):302.

23- Costa J, Alarcão J, Araujo F, Ascenção R, Caldeira D, Fiorentino F, et al. The burden of atherosclerosis in Portugal. Eur Heart J Qual Care Clin Outcomes. 2020 Sep 18;7(2):154–62.

24- Kang MK, Shin DG, Han D, Choi S, Cho JR, Lee N. Prevalence of stable coronary artery disease and its associated clinical factors among patients with chest pain and elevated cardiac troponin alone. Heliyon. 2023 Apr;9(4):e15261.

25- Frančula-Zaninović S, Nola IA. Management of Measurable Variable Cardiovascular Disease’ Risk Factors. Curr Cardiol Rev. 2018 Aug;14(3):153–63.

26- Ashour K. Acute coronary syndromes in premenopausal women: Clinical and angiographic findings. Mustansiriya Med J. 2017;16(3):19.

27- Salehi N, Janjani P, Tadbiri H, Rozbahani M, Jalilian M. Effect of cigarette smoking on coronary arteries and pattern and severity of coronary artery disease: a review. J Int Med Res. 2021 Dec 2;49(12):03000605211059893.

28- Wang X, Xu W, Song Q, Zhao Z, Meng X, Xia C, et al. Association between the triglyceride–glucose index and severity of coronary artery disease. Cardiovasc Diabetol. 2022 Sep 1;21:168.

29- Dababneh E, Goldstein S. Chronic Ischemic Heart Disease Selection of Treatment Modality. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Aug 14]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK507703/

30- Fadhil S, Elaebi H, Abbas S. Assessment of the left ventricular performance in hypertensive patients with normal coronary angiography and ejection fraction: Insight by two-dimensional speckle tracking echocardiography. Mustansiriya Med J. 2022;21(1):68.

31- Shatari SAEA, Juboori YBHA, Salih K, Abed AS, Gabur AS, Witwit SA, et al. Effect of Health education on Blood Pressure Control & Life Modification in Hypertensive Patients: Sample from Primary Health Care centers, Al -Rusafa Sector/Baghdad. IRAQI JOURNAL OF COMMUNITY MEDICINE [Internet]. 2021 [cited 2023 Oct 26];34(2). Available from: https://www.iasj.net/iasj/article/234318

32- Cojocaru M, Cojocaru IM, Silosi I. Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases. Maedica (Bucur). 2010 Jan;5(1):51–5.

33- Devaraj S, Semaan JR, Jialal I. Biochemistry, Apolipoprotein B. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Dec 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK538139/

34- Jain K, Vadak N, Bhatt LK. Chapter 5 - Phospholipase A2: An emerging biomarker in vascular diseases. In: Chakraborti S, editor. Phospholipases in Physiology and Pathology [Internet]. Academic Press; 2023 [cited 2023 Dec 28]. p. 85–103. Available from: https://www.sciencedirect.com/science/article/pii/B9780443153136000028

35- Packard CJ. CHAPTER 14 - Role of Lipoprotein-Associated Phospholipase A2 in Vascular Disease. In: Ballantyne CM, editor. Clinical Lipidology [Internet]. Philadelphia: W.B. Saunders; 2009 [cited 2023 Dec 28]. p. 167–77. Available from: https://www.sciencedirect.com/science/article/pii/B9781416054696500184

36- Zhang L, Li Z, Li N. Serum IMA and LP-PLA2 Levels in Patients with Coronary Heart Disease and Their Correlation with the Degree of Myocardial Ischaemia and Their Diagnostic Value. Emerg Med Int. 2022 Jun 11; 2022:1698315.

37- Zhang H, Gao Y, Wu D, Zhang D. The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease. BMC Cardiovasc Disord. 2020 Jun 16; 20:295.

38- Farhood HH, Abdulridha MK, Hadi H. The Association between Adverse Pregnancy Outcomes and Laboratory Measures as Risk for Cardiovascular Disorders. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2023 May 22;23(2):127–39.

39- Zhai Y, Cao X, Liu S, Shen Y. The diagnostic value of lipoprotein-associated phospholipase A2 in early diabetic nephropathy. Ann Med. 55(2):2230446.